Table 11 Sensitivity analysis
Country | Parameter | ICER range# | 3xGDP $* | |
|---|---|---|---|---|
Argentina | Efficacy in preventing NTHI AOM (CI 95%) | $6,689.27 | $3,753.22 | $ 22,277 |
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) | $5,959.08 | $3,724.97 | ||
AOM - Etiology (Sp -/+ 20%) | $5,701.40 | $3,886.36 | ||
AOM -Disutility for hearing loss (CI 95%) | $5,622.58 | $3,982.36 | ||
Efficacy in preventing Sp AOM (CI 95%) | $5,501.06 | $3,989.9 | ||
Brazil | Bacteremia-Incidence (+/-50%) | $10,397.98 | $6,021.45 | $ 24,884 |
Efficacy in preventing hospitalization for pneumonia (CI 95%) | $9,393.87 | $6,311.59 | ||
Meningitis-Incidence (-/+50%) | $8,758.52 | $6,667.62 | ||
Vaccine efficacy ramp-up (-/+ 20%, CI 95%) | $8,526.38 | $6,920.00 | ||
Efficacy in preventing invasive disease (CI 95%) | $8,035.13 | $7,261.63 | ||
Colombia | Efficacy in preventing hospitalization for pneumonia (CI 95%) | $5,208.56 | $3,195.50 | $ 14,966 |
Efficacy in preventing NTHI AOM (CI 95%) | $5,039.76 | $3,502.43 | ||
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) | $4,864.28 | $3,381.48 | ||
AOM - Etiology (Sp -/+ 20%) | $4,775.73 | $3,433.84 | ||
AOM -Disutility for hearing loss (CI 95%) | $4,781.43 | $3,469.80 | ||
Mexico | Efficacy in preventing NTHI AOM (CI 95%) | $6,909.40 | $3,408.91 | $ 30,598 |
Efficacy in preventing hospitalization for pneumonia (CI 95%) | $6,638.91 | $3,181.98 | ||
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) | $5,830.11 | $3,564.65 | ||
Bacteremia-Incidence (+/-50%) | $5,894.39 | $3,704.39 | ||
AOM - Incidence (Myringotomies -/+ 20%, Total Cases -/+ 50%) | $5,364.50 | $3,839.01 | Â | |
Peru | Efficacy in preventing hospitalization for pneumonia (CI 95%) | $3,813.47 | $2,422.55 | $ 13,129 |
AOM -Disutility for hearing loss (CI 95%) | $3,649.05 | $2,511.47 | ||
Efficacy in preventing NTHI AOM (CI 95%) | $3,706.67 | $2,617.21 | ||
AOM - Etiology (Sp -/+20%, NTHI -/+ 40%) | $3,577.81 | $2,535.13 | ||
| Â | AOM - Etiology (Sp -/+ 20%) | $3,513.24 | $2,570.60 | Â |